Abivax is set to release its first-half earnings report, with analysts expecting a loss of $1.08 per share on $1.86 million in revenue. Several analysts have recently reiterated Buy/Overweight ratings and raised price targets, indicating positive sentiment ahead of the earnings call.
This filing announces that Abivax (ABVX) will release its first-half earnings report after the market close on Monday, September 21st. The key information is the consensus analyst expectation of a $1.08 loss per share and $1.86 million in revenue, coupled with recent positive analyst revisions (upgrades and price target increases) from firms like Piper Sandler, Truist, Citizens, and Jefferies. This matters because analyst sentiment and expectations often influence short-term stock price movements around earnings. For traders, the immediate opportunity lies in anticipating how the actual earnings compare to these revised expectations, especially given the recent positive FDA interaction for Obefazimod. A beat on revenue or a smaller loss than expected, or positive commentary on Obefazimod, could lead to a short-term rally, while a miss could trigger a pullback despite the generally positive analyst outlook.